Vanda Pharmaceuticals faces a challenging outlook characterized by inconsistent revenue growth and an aggressive, capital-intensive litigation strategy that continues to erode shareholder equity. While the company maintains high gross margins near 93%, these a...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | -$1.04-78.5% vs -$0.58 | $51M-18.4% vs $62M |
Q2 2026 May 6, 2026 | -$0.82-54.7% vs -$0.53 | $52M-5.9% vs $55M |
Q1 2026 Feb 11, 2026 | -$2.39-9.6% vs -$2.18 | $57M-3.5% vs $59M |
Q4 2025 Oct 29, 2025 | -$0.38-22.6% vs -$0.31 | $56M-5.1% vs $59M |
WASHINGTON, Sept. 2, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate at the following upcoming investor conferences in September 2026: The Wells Fargo 21st Annual Healthcare Conference in Boston on Tuesday, September 8, 2026.
WASHINGTON, Aug. 24, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that its investigational drug imsidolimab has received Orphan Designation from the European Commission, based on the positive opinion received from the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP), for the treatment of Generalized Pustular Psoriasis (GPP), which is a severe, chronic, and potentially life-threatening inflammatory skin disease driven by dysregulation in the interleukin-36 (IL-36) signaling pathway.1 The US Food and Drug Administration (FDA) and Japan's Ministry of Health, Labour and Welfare have previously granted Orphan Drug Designation to imsidolimab for the treatment of GPP. This marks the first time the European Commission has granted orphan designation recognition for a drug to treat GPP in the European Union (EU).
NEREUS⢠Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C. PR Newswire WASHI
WASHINGTON, Aug. 22, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the NEREUS™ branded No. 47 entry from Rahal Letterman Lanigan Racing, driven by Mick Schumacher, is set to compete this weekend in the inaugural Freedom 250 Grand Prix of Washington, D.C.
Benchmark VNDA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Vanda Pharmaceuticals Inc. (VNDA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.04 | $303.08M | -1.35 | 8.72% | -102.02% | -50.93% | — | |
| $43.39 | $2.52B | -63.81 | 8.63% | -13.23% | -10.42% | — | |
| $62.34 | $5.17B | 8.01 | 114.51% | -3.8% | — | — | |
| $25.43 | $4.35B | 11.10 | 11.87% | 33.42% | 32.39% | — | |
| $20.24 | $1.49B | 6.13 | 18.52% | 80.56% | 30.03% | — | |
| $24.63 | $968.82M | 153.94 | 3.63% | 1.96% | 2.13% | — |
Vanda Pharmaceuticals Inc. (VNDA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Vanda Pharmaceuticals Inc. (VNDA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jun 5, 2026·SEC
May 6, 2026·SEC
Get notified when VNDA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Vanda Pharmaceuticals Inc. (VNDA) stock FAQ — growth, dividends, profitability & financials explained
Vanda Pharmaceuticals Inc. (VNDA) reported $215.7M in revenue for fiscal year 2025. This represents a 634747% increase from $0.0M in 2004.
Vanda Pharmaceuticals Inc. (VNDA) grew revenue by 8.7% over the past year. This is steady growth.
Vanda Pharmaceuticals Inc. (VNDA) reported a net loss of $274.9M for fiscal year 2025.
Vanda Pharmaceuticals Inc. (VNDA) has a return on equity (ROE) of -50.9%. Negative ROE indicates the company is unprofitable.
Vanda Pharmaceuticals Inc. (VNDA) had negative free cash flow of $193.4M in fiscal year 2025, likely due to heavy capital investments.
